Serina Therapeutics, Inc. (SER)
ASE · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.6M | -6.4M | -6.2M | -6.3M |
| Net Income | -6.4M | -4.6M | -3.3M | -6.9M |
| Diluted EPS | $-0.66 | $-0.45 | $nan | $-0.58 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 500K | 3.0M | 0.00 | 0.00 |
| Operating Income | -2.3M | -3.1M | -17.0M | -24.0M |
| Net Income | -2.7M | 5.3M | -11.1M | -19.2M |
| Diluted EPS | $-1.23 | $0.63 | $-1.51 | $-1.91 |